| Family-Based Behavioral Treatment for Childhood Survivors of Acute Lymphoblastic Leukemia (NCT05410574) | Washington University School of Medicine | 2022-07-22 |
| Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia (NCT05563545) | Shanghai Simnova Biotechnology Co.,Ltd. | 2022-07-21 |
| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT05139004) | City of Hope Medical Center | 2022-07-19 |
| Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma (NCT05037669) | University of Pennsylvania | 2022-07-01 |
| A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) (NCT05386576) | Memorial Sloan Kettering Cancer Center | 2022-06-16 |
| A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (NCT05268003) | M.D. Anderson Cancer Center | 2022-06-07 |
| CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) (NCT03768310) | Baylor College of Medicine | 2022-06-01 |
| Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (NCT03399773) | Fred Hutchinson Cancer Center | 2022-05-10 |
| Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients (NCT05433532) | The First Affiliated Hospital of Soochow University | 2022-05-01 |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study (NCT04726241) | PedAL BCU, LLC | 2022-04-18 |
| Observational Study on Invasive Fungal Infection Incidence in Ph-neg Acute Lymphoblastic Leukemia Patients (NCT06392581) | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 2022-04-14 |
| The Patient Cohort of the National Center for Precision Medicine in Leukemia (NCT05326919) | Assistance Publique - Hôpitaux de Paris | 2022-03-28 |
| Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States (NCT04928599) | Children's Oncology Group | 2022-03-14 |
| A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia (NCT05326516) | Syndax Pharmaceuticals | 2022-03-09 |
| To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. (NCT05223686) | Hrain Biotechnology Co., Ltd. | 2022-02-10 |
| A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents (NCT05334823) | Chongqing Precision Biotech Co., Ltd | 2022-01-26 |
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330) | Biomea Fusion Inc. | 2022-01-24 |
| Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT (NCT05809167) | The First Affiliated Hospital of Soochow University | 2022-01-20 |
| Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL (NCT05578378) | The First Affiliated Hospital of Soochow University | 2022-01-01 |
| Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL (NCT05252403) | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | 2021-12-01 |
| Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic Leukemia (NCT05133310) | Hospital General de Mexico | 2021-11-19 |
| Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy (NCT04975555) | University of Alabama at Birmingham | 2021-11-15 |
| Two Step Haplo With Radiation Conditioning (NCT05031897) | Thomas Jefferson University | 2021-10-25 |
| How Effective is the Dose-graded Aerobic Training in Children Survivors of Acute Lymphoblastic Leukemia? (NCT05679817) | Cairo University | 2021-10-03 |
| A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL (NCT05054465) | Israeli Medical Association | 2021-10-01 |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (NCT04904588) | Center for International Blood and Marrow Transplant Research | 2021-09-30 |
| Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings (NCT04969601) | Assistance Publique - Hôpitaux de Paris | 2021-09-29 |
| Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT (NCT04764513) | Chinese PLA General Hospital | 2021-09-12 |
| Backtracking Leukemia-Typical Somatic Mutations in Cord Blood (NCT05014165) | Children's Oncology Group | 2021-08-25 |
| SPARK-ALL: Calaspargase Pegol in Adults With ALL (NCT04817761) | Institut de Recherches Internationales Servier | 2021-07-07 |
| MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies (NCT04762875) | Ensoma | 2021-06-16 |
| A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL) (NCT04956666) | Institut de Recherches Internationales Servier | 2021-06-15 |
| Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study (NCT05972577) | Ohio State University Comprehensive Cancer Center | 2021-06-11 |
| huCART19-IL18 in CD19+ Cancers (NCT04684563) | University of Pennsylvania | 2021-05-06 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment (NCT04028479) | Taproot Health | 2021-05-05 |
| Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies (NCT04732845) | Benjamin Tomlinson | 2021-04-26 |
| TDM of Asparaginase in ALL2008 (NCT04843514) | Aarhus University Hospital | 2021-04-01 |
| Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors (NCT04814004) | Kai Lin Xu; Jun Nian Zheng | 2021-03-19 |
| Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies (NCT04796688) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2021-03-10 |
| CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML (NCT04787263) | Bambino Gesù Hospital and Research Institute | 2021-03-04 |
| Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) (NCT04747912) | University of Chicago | 2021-03-02 |
| Methods of T Cell Depletion Trial (MoTD) (NCT04888741) | University of Birmingham | 2021-02-22 |
| Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT (NCT04629430) | University of Virginia | 2021-02-19 |
| Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia (NCT05326984) | Hospital General de Mexico | 2021-02-09 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (NCT04195633) | Fred Hutchinson Cancer Center | 2021-01-25 |
| Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) (NCT04095858) | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2021-01-05 |
| A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies (NCT04689204) | He Huang | 2020-12-29 |
| Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study (NCT04537871) | City of Hope Medical Center | 2020-11-18 |
| Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia (NCT04606433) | Sichuan Baili Pharmaceutical Co., Ltd. | 2020-11-04 |
| A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies (NCT04532203) | Zhejiang University | 2020-11-01 |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies (NCT03272633) | Rutgers, The State University of New Jersey | 2020-10-26 |
| Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL) (NCT04225676) | Novartis Pharmaceuticals | 2020-10-19 |
| CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (NCT04049383) | Medical College of Wisconsin | 2020-10-16 |
| Assesment of JL1 Expression in Acute Leukemia (NCT04554381) | Assiut University | 2020-10-13 |
| Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL (NCT04524455) | Amgen | 2020-10-02 |
| SARS-CoV-2 Donor-Recipient Immunity Transfer (NCT04666025) | City of Hope Medical Center | 2020-09-23 |
| Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19 (NCT04452604) | French Innovative Leukemia Organisation | 2020-09-11 |
| Clinical Significance of Occult Central Nervous System Localization (NCT05772000) | University of Rome Tor Vergata | 2020-09-08 |
| Vitamin D and Methotrexate Adverse Effects (NCT04488237) | Assiut University | 2020-09-01 |
| A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL (NCT04532268) | Zhejiang University | 2020-08-23 |
| Haplo Peripheral Blood Sct In GVHD Prevention (NCT04473911) | Zachariah Michael DeFilipp | 2020-08-14 |
| Forecasting Hypersensitivity Against PEG-asparaginase to Optimize Outcome in ALL (NCT06195735) | Aarhus University Hospital | 2020-07-17 |
| The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation (NCT04233346) | Otsuka Beijing Research Institute | 2020-07-09 |
| Post-thrombotic Syndrome After Deep Venous Thrombosis (DVT) in Patients Treated According to the NOPHO ALL2008 Protocol (NCT04825548) | Aarhus University Hospital | 2020-07-01 |
| Pharmacokinetics and Immunogenicity of the First Doses of PEG-Asparaginase -An ALLTogether Pilot Study (NCT04843150) | Aarhus University Hospital | 2020-07-01 |
| Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL) (NCT03668392) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2020-06-25 |
| Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia (NCT03628053) | Novartis Pharmaceuticals | 2020-06-05 |
| Study of Anti-CD22 CAR-T Cells Treating Leukemia Children (NCT04340167) | Beijing Boren Hospital | 2020-05-01 |
| Study of Sequential CAR-T Cell Treating Leukemia Children (NCT04340154) | Beijing Boren Hospital | 2020-05-01 |
| Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (NCT04329325) | Memorial Sloan Kettering Cancer Center | 2020-03-30 |
| TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (NCT04323657) | TCR2 Therapeutics | 2020-03-27 |
| CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML (NCT04151706) | Robert Lowsky | 2020-02-27 |
| Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia (NCT04262843) | City of Hope Medical Center | 2020-02-07 |
| A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy (NCT04226989) | He Huang | 2020-02-05 |
| Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide (NCT03533816) | University of Kansas Medical Center | 2020-01-31 |
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors (NCT03934372) | Incyte Biosciences International Sàrl | 2020-01-29 |
| A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy (NCT04227015) | He Huang | 2020-01-08 |
| Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic VOD in Children With Nephroblastoma or ALL (NCT04168788) | University Hospital, Angers | 2020-01-01 |
| An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) (NCT04145531) | Jazz Pharmaceuticals | 2019-12-27 |
| Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy (NCT04014764) | Notable Labs | 2019-12-15 |
| Neurostimulation In Adult Survivors of Childhood Acute Lymphoblastic Leukemia (ALL) (NCT04007601) | St. Jude Children's Research Hospital | 2019-12-12 |
| CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia (NCT04154709) | Kai Lin Xu; Jun Nian Zheng | 2019-12-10 |
| Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies (NCT04191187) | H. Lee Moffitt Cancer Center and Research Institute | 2019-12-06 |
| Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation (NCT04060277) | City of Hope Medical Center | 2019-11-27 |
| Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL) (NCT04105530) | St. Jude Children's Research Hospital | 2019-11-18 |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (NCT04065399) | Syndax Pharmaceuticals | 2019-11-05 |
| Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents (NCT04888468) | Chongqing Precision Biotech Co., Ltd | 2019-11-05 |
| Effect of Vitamin D Diffiency on Oral Mucosa in Patients Recieving Methotrexate Chemotherapy (NCT04096846) | Assiut University | 2019-11-01 |
| Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation (NCT03856216) | M.D. Anderson Cancer Center | 2019-10-28 |
| A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia (NCT04067518) | Institut de Recherches Internationales Servier | 2019-10-17 |
| CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (NCT03765177) | Ottawa Hospital Research Institute | 2019-10-16 |
| Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL (NCT04206943) | Acibadem University | 2019-10-12 |
| Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft (NCT03887156) | Assistance Publique - Hôpitaux de Paris | 2019-09-16 |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia (NCT04067336) | Kura Oncology, Inc. | 2019-09-12 |
| Correlation of Polymorphisms of Lipoprotein Lipase (LpL) and Apolipoprotein E (Apo E) With Lipid Profile of Children With Acute Lymphoblastic Eukaemia During Therapy With L - Asparaginase. (NCT04364451) | Aristotle University Of Thessaloniki | 2019-09-01 |
| Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant (NCT03779854) | Fred Hutchinson Cancer Center | 2019-08-29 |
| Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL (NCT03919526) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2019-08-11 |
| Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (NCT03860844) | Sanofi | 2019-08-06 |
| Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies (NCT04007978) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2019-08-05 |
| Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia (NCT03187691) | Matinas BioPharma Nanotechnologies, Inc. | 2019-08-01 |